Azelis included in Euronext’s BEL20 Index 13 June 2024 Azelis, a leading innovation service provider in the specialty chemicals and food ingredients industry, is proud to announce that it has been included in the BEL20 index, the benchmark stock market index of Euronext Brussels, consisting of the 20 largest traded companies in Belgium. This inclusion, effective June 24th, is a testament to Azelis’ strong positioning, performance, and commitment to providing value to all stakeholders. The BEL20 tracks the performance of 20 companies in Belgium with the largest free-float market capitalization, and the composition of the index is reviewed annually. As one of Euronext’s blue-chip indices, the BEL20 serves as an underlying benchmark for structured products, funds, exchange traded funds, options and futures. Anna Bertona, Azelis Group CEO, comments: “We are pleased to be included in the BEL20 index just a few short years after our IPO. This inclusion is a significant milestone for Azelis and is a clear signal of our growth and progress as one of 20 indicators for the Belgian stock market. This recognition also demonstrates to our customers, principals, and shareholders that Azelis is committed to furthering our commercial and operational performance by providing sustainable and innovative formulations. As a company proudly headquartered in Belgium, we’re honored to increase the visibility of Azelis in our home market and play an important role in the Belgian economy.”
Sophie Sepulchre’s Post
More Relevant Posts
-
#GraphOfTheWeek The 14 Danish stocks tracked by AlphaValue have given growth and valuation lessons to their Stoxx600 peers for more than 10 years. With the craze for weight-loss drugs pushing Novo Nordisk to a market cap above €400bn, that universe knew no ceiling. Then the tensions on long rates acted as a reset: Novo has lost c. 6% over the last two weeks. So did its Danish cousins, shedding a collective 3.5%. This opens up only a 7% upside as Novo is still too expensive. Ex Novo the 13 stocks post a combined upside potential which is becoming attractive at +26%. Danish corporates are as impressive as ever and should be held on any weakness. #Danish #EquityResearch #Valuation
To view or add a comment, sign in
-
-
📊New cash market trading volumes for 2023 out now: In total, Deutsche Börse’s #CashMarkets generated a turnover of €1.2 trillion last year on the #trading venues Börse Frankfurt and Xetra Trading. SAP SE, Lufthansa AG, MorphoSys AG and Formycon AG were the most actively traded #stocks in the indices #DAX, MDAX, SDAX und Scale All Share last year. In the #ETF segment the iShares Core MSCI World achieved the largest volume on Xetra in 2023 with €6.1 billion. Order book turnover in December 2023 totalled €97.4 billion after €92 billion in the previous year. Of this amount, €94.1 billion was attributable to Xetra and €3.3 billion to Börse Frankfurt. The average daily turnover on Xetra in December was €5 billion. Find further information and #statistics in today's press release: 🔗https://lnkd.in/egD5GCTQ
To view or add a comment, sign in
-
-
#dionice #ulaganje The National Securities Market Commission (CNMV) decided on Monday to suspend trading in Grifols shares as a precautionary measure. It did so with immediate effect just 10 minutes before the European stock market opened and almost immediately after the biotechnology company itself issued a statement through the supervisory body, announcing that the founding family ( the Grifols ) and the private equity fund Brookfield were considering joining forces to buy all of the company's capital and delist it from the stock market (both in Spain and the United States). Trading was finally halted for only three hours, until 12:00 (Madrid time). Once reactivated, it rose sharply, 20% to over 10.8 euros per share. From the beginning of the year until the close of last Friday, the price of shares quoted on the Ibex had plummeted by more than 40% due to the debt and, above all, credibility crises that broke out at the beginning of January. The board of directors of the Catalan company met yesterday, Sunday 7 July, in an extraordinary session. The reason was compelling: the founding family ("the family shareholders of Grifols", according to the notification to the CNMV) and Brookfield Capital Partners Limited made a request to be allowed to consult "certain information" of the manufacturer of blood derivatives. The purpose of Grifols and the private equity firm is to carry out a due diligence , that is, to thoroughly investigate the real state of the group. They are considering making a joint takeover bid (OPA) for all of Grifols' share capital (100%). Kupio sam po 9.94..sad da vidim ima li stvarno vatre gdje ima i dima.
To view or add a comment, sign in
-
The NASDAQ-100 is an index that is constituted by 100 of the largest companies listed on the NASDAQ stock exchange, which is the second largest in the world only after the New York Stock Exchange by market capitalization. The companies that are listed in this index range from a variety of industries like Technology, Telecommunications, Biotechnology, Media, and Services. The NASDAQ-100 was first calculated in January 31 of 1985 by NASDAQ and it is a modified capitalization-weighted index. This index has been of good reference to investors that want to know how the stock market is performing without financial services companies, this given that the index excludes financial companies.
To view or add a comment, sign in
-
Fresenius Group is approaching our target at 27. We sent this stock picking to all our clients at the beginning of April. Why we were bullish ? 👇 1 - The stock bounced off the line joining the bottom since March 2023 with a bullish price action called "Engulfing". 2 - Same configuration on the Rsi indicator. 3 - Our proprietary timing indicator told us that the drop from December 2023 were close to the end. For more informations, do not hesitate to contact us : contact@tecknike.com #technicalanalysis #equityresearch #stockmarket #investment #hedgefund #portfoliomanagement #equity #stock #assetmanagement #finance #stockpicking #Fresenius
To view or add a comment, sign in
-
-
Is the Grey Market Premium (GMP) truly a reliable indicator? 📈💼 Recent market shifts suggest a changing landscape, urging a closer examination for those banking on GMP for listing gains. Let's delve into the intricacies of recent events. 💡 📌 Consider the case of the Mukka Proteins IPO, where despite a promising GMP of 125%, the actual listing on March 7th, 2024, reflected a mere 42% premium. 📌 Similarly, the Sona Machinery SME IPO, boasting a 70% GMP on its last subscription day, faced a surprising negative listing, resulting in a 12.58% decline. 📌 Even amidst heavy subscription, the Koura Fine Diamond Jewelry Limited IPO saw a GMP of approximately 118%, yet its listing gain amounted to just 36.36%. 📌 Could these fluctuations be attributed to the recent statement by the SEBI Chairman regarding overvaluation in mid-caps and small caps, directly influencing IPO listings? If this narrative resonates with your experience, i invite you to share your insights! Join this conversation for more in-depth analyses and engaging discussions. 🔍💬 #Stockmarket #Finance #Business #India #startups #financial #markets
To view or add a comment, sign in
-
The latest edition of The IPOX® Week #737 is now available here: https://lnkd.in/gN4kqaWJ Read about the impressive performance of our thematic IPOX® Indexes focused on Health Innovation and ESG and the reaction of European IPOX® Indexes to ECB rate cuts after their strong momentum in May. Notable upcoming listings include QuantumPharm in Hong Kong, Raspberry Pi in London, as well as Telix Pharmaceuticals Limited and Tempus AI in New York, as global IPO activity heats up. Stay informed with our IPO Calendar and social media updates for the latest on upcoming IPOs and market trends. #IPO #MarketAnalysis #Investing #Finance #IPOX #ETF
To view or add a comment, sign in
-
The latest edition of The IPOX® Watch is now available: IPOX® Indexes face profit-taking pressure after 2023 growth momentum. Analysts see strong M&A momentum in 2024 with focus on biopharma. International holdings outperform U.S. amid early-year tech rout. Read here: https://lnkd.in/g82aBH4X #IPO #Indexing #ETF #FPX #FPXI #FPXE #SP500 #StockMarket
The IPOX® Week #715 — IPOX
ipox.com
To view or add a comment, sign in
-
January was a strong month for Australian investors in global stocks, with our portfolio +4.4% gross. Is our positive view on the portfolio tempered by overnight US CPI data? Not really, I think relationship between inflation and stock valuations is terribly understood by markets and fundamentally this isn't a big deal. But people over-react! And so we're watching stock volatility measures for panic, and listening to earnings calls for underlying signs of recession. Our biggest concern at the moment is persistent costs derailing profit margins - and our biggest disappointment is how much cash companies are burning firing workers and writing it off as restructures - false economics!
The BML Global Fund returned 4.4% gross to investors in January, taking total returns since inception to 11.1%, beating the benchmark by 4.1%. This month Australian investors benefited from holding US dollar assets as the Australian dollar weakened, as well as strong technology and pharmaceutical stocks. BML still views our portfolio as undervalued, and despite high multiples on the largest stocks, we are optimistic on markets for 2024. Returns are AUD, gross of fees, and the BML Global Fund is for wholesale investors. For full disclaimer, see attached report.
To view or add a comment, sign in
-
It’s been a big month here at Cynata and according to Stockhead, we are among the top 50 stocks that shone brightly in May. Delighted to see our innovative approach to regenerative medicine is making waves and capturing investor attention. Check out the full article here: https://bit.ly/4bJGnFa #ASX #investing #biotech #regenerativemedicine #investors
ASX May Winners: The best 50 stocks as inflation continues to weigh on markets - Stockhead
https://stockhead.com.au
To view or add a comment, sign in